Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium avium complex: so near and yet so far.

Sanjay SinghGunavanthi D BoorgulaSantosh AryalJulie V PhilleyTawanda GumboShashikant Srivastava

Published in: The Journal of antimicrobial chemotherapy (2023)

Sarecycline demonstrated anti-MAC Emax in the HFS-MAC model better than ethambutol but worse than omadacycline (>5 log10 cfu/mL below stasis) in HFS-MAC. However, since currently approved highest oral sarecycline dose achieves an AUC0-24 of 48.2 mg·h/L and MAC MICs are >32 mg/L, the target AUC0-24/MIC of 139.46 is unlikely to be achieved in patients.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
mycobacterium tuberculosis
prognostic factors
peritoneal dialysis
patient reported outcomes
mass spectrometry
tandem mass spectrometry